Therefore, REGγ is a promising therapeutic target for endometrial cancer with the p53-R248Q mutation (27).TP53 mutations tend to be associated with a poorer prognosis in cancer because the mutant p53 they produce often leads to loss of apoptotic function and the ability to arrest the cell cycle. Here, TP53 is linked to cancer.